Added
Updated
Alacrita
Alacrita is a life sciences consulting firm advising pharma and biotech clients on drug development and strategy.
Founded
2009Alacrita is a life sciences consulting firm advising pharma and biotech clients on drug development and strategy.
Alacrita is a fee-for-service life sciences consulting firm serving pharmaceutical, biotechnology, and investor clients from London and Cambridge, Massachusetts. The company raises no investment rounds and deploys no capital, earning revenue from advisory engagements across development and transaction decisions.
Key people include Managing Partners Anthony Walker and Alastair Southwell alongside Partner Mark Philip, with co-founder Rob Johnson formerly serving as Managing Partner. No change of control of Alacrita is evidenced, and the firm continues to operate under its own brand with operating status Operating.
Alacrita provides consulting services across product development from discovery through clinical strategy for pharmaceutical and biotechnology organizations. Offerings include preclinical drug development support covering target identification and validation, assay development, hit-to-lead, lead optimization, and candidate selection.
Enterprise development services cover fundraising support, interim leadership, and organizational growth, while business development work includes due diligence and licensing advisory. The firm also provides investor services and expert witness engagements staffed from its specialist network.
Alacrita fields project teams from a network of more than three hundred industry specialists with direct operating experience in drug development. This model gives clients access to practitioners who have led discovery, clinical, regulatory, and manufacturing work inside pharmaceutical and biotechnology companies.
The firm combines London and Cambridge, Massachusetts offices with coverage across product, enterprise, and business development services in one engagement. Operating history since 2009 and named engagements with listed biotechnology companies evidence repeat demand for its advisory capacity.